BioClinica, Inc. to Present at the 11th Annual JMP Securities Research Conference in San Francisco on May 14, 2012

11th Annual JMP Securities Research Conference

NEWTOWN, Pa.--()--BioClinica®, Inc. (NASDAQ: BIOC) today announced Mark L. Weinstein, President and Chief Executive Officer will be presenting at the 11th Annual JMP Securities Research Conference in San Francisco on Monday, May 14, 2012 at 4:00 p.m. PDT.

Mr. Weinstein will be discussing an overview of BioClinica, its business strategy and financial performance.

The Company will provide a live webcast of the presentation. To access this presentation, listeners should go to the following link, approximately 15 minutes prior to the event to register and download any necessary software:

http://www.bioclinica.com/Investors/investor-events/

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Contacts

BioClinica, Inc.
Jim Dorsey, 267-757-3040
or
Porter, LeVay & Rose, Inc.
Investors – Michael Porter
Financial Media - Bill Gordon
212-564-4700

Release Summary

BioClinica will be presenting at the JMP Securities Research Conference on May 14, 2012 in San Francisco. Mark Weinstein will update investors on the company's progress, and it will be webcast.

Sharing

Contacts

BioClinica, Inc.
Jim Dorsey, 267-757-3040
or
Porter, LeVay & Rose, Inc.
Investors – Michael Porter
Financial Media - Bill Gordon
212-564-4700